|Bid||0.00 x 1000|
|Ask||0.00 x 2200|
|Day's Range||19.59 - 21.38|
|52 Week Range||3.67 - 38.50|
|Beta (5Y Monthly)||3.92|
|PE Ratio (TTM)||N/A|
|Earnings Date||Jul 26, 2021 - Jul 30, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||38.00|
Flagship Pioneering, the bioplatform innovation company, announced today that Stephen Hahn, M.D. will help lead its Preemptive Medicine and Health Security initiative as Chief Medical Officer, and join Flagship's Senior Leadership Team, effective June 16, 2021. Dr. Hahn served as the U.S. Food and Drug Administration Commissioner from 2019–2021. Prior to joining the FDA, he was the Chief Medical Executive, The University of Texas MD Anderson Cancer Center.
Seres Therapeutics, Inc. (Nasdaq: MCRB) today announced that it will host a virtual investor event focused on SER-287 and SER-301, potential new therapeutic options for ulcerative colitis (UC) on Monday, June 21, 2021 from 8:30 a.m. to 10:00 a.m. ET.
Seres Therapeutics, Inc., (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that Terri Young, Ph.D., R.Ph., Chief Commercial and Strategy Officer of Seres Therapeutics, will present at the JMP Securities Life Sciences Conference on Thursday, June 17, 2021 at 1:00 p.m. ET.